TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37979717

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose heparin
Number of subjects: 727

Group type: COMPARATOR
Intervention: Prophylactic heparin
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Presence of 90-day symptoms
Number of subjects: 727
Study: 37979959

Group type: EXPERIMENTAL
Intervention: Avacopan
Number of subjects: 330

Group type: COMPARATOR
Intervention: Prednisone taper
Number of subjects: 330
Study: 37980367

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus CC-115 (5 mg twice a day)
Number of subjects: 41
Study: 37980467

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine
Number of subjects: 63
Study: 37980472

Group type: EXPERIMENTAL
Intervention: Frequent condom negotiation with partners
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Frequent binge drinking in the past month (n=177)
Number of subjects: 500
Study: 37980484

Group type: EXPERIMENTAL
Intervention: Integrated community-based intervention package including video and audio information on safe motherhood, birth preparedness card, training for community volunteers and health extension workers, and improved maternity waiting home services.
Number of subjects: 727

Group type: COMPARATOR
Intervention: Routine services only (Control group).
Number of subjects: 727
Study: 37980490

Group type: EXPERIMENTAL
Intervention: Self-management intervention for urinary incontinence (SMI-UI) including a mobile application, handbook, and professional support.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control group receiving a single dietetic education information package.
Number of subjects: 0
Study: 37980494

Group type: EXPERIMENTAL
Intervention: STOP intervention (practice-embedded nurse care manager, brief advice from PCP, up to 6 sessions of telephone health coaching)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) (primary care treatment as usual, printed overdose prevention educational materials, educational video on cancer screening)
Number of subjects: 0
Study: 37980511

Group type: EXPERIMENTAL
Intervention: Bladder-sparing therapies (BST)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Radical cystectomy
Number of subjects: 572
Study: 37980687

Group type: EXPERIMENTAL
Intervention: ABM training (N=16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (N=16)
Number of subjects: 32
Study: 37980767

Group type: EXPERIMENTAL
Intervention: Pre-clinical (PC) group
Number of subjects: 1133

Group type: COMPARATOR
Intervention: Clinically diagnosed (CD) group
Number of subjects: 1133
Study: 37980801

Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 95
Study: 37980875

Group type: EXPERIMENTAL
Intervention: Group iterative multiple model estimation (GIMME) applied to examine the relationships between various emotions and suicidal ideation (SI) among individuals with borderline personality disorder who underwent Dialectical Behavior Therapy.
Number of subjects: 0
Study: 37980911

Group type: EXPERIMENTAL
Intervention: BPaLM
Number of subjects: 552

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 552
Study: 37980921

Group type: EXPERIMENTAL
Intervention: Systemic and local therapy group (n=53)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Systemic therapy only group (n=51)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 37980922

Group type: EXPERIMENTAL
Intervention: Upfront endoscopic necrosectomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Step-up treatment
Number of subjects: 70
Study: 37980924

Group type: EXPERIMENTAL
Intervention: Apixaban (weight-adjusted twice-daily)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Standard of Care (SOC, no systemic anticoagulation)
Number of subjects: 512
Study: 37981049

Group type: EXPERIMENTAL
Intervention: SY-009 (1.0-4.0 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 37981090

Group type: COMPARATOR
Intervention: First-line osimertinib
Number of subjects: 891

Group type: COMPARATOR
Intervention: Later-line osimertinib
Number of subjects: 891
Study: 37981473

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination
Number of subjects: 26
Study: 37981564

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: CART therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-CD20 antibody-based regimens
Number of subjects: 0
Study: 37981596

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 12 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deucravacitinib (both doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 37981662

Group type: EXPERIMENTAL
Intervention: Behavioral model-guided nutritional counseling
Number of subjects: 263
Study: 37981665

Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Curcumin gel applied weekly for four weeks after SRP
Number of subjects: 54

Group type: COMPARATOR
Intervention: Negative control group (healthy gingiva)
Number of subjects: 54
Study: 37981893

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Decision aid impact
Number of subjects: 123
Study: 37981892

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) and 'on-demand' plerixafor
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 301
Study: 37982152

Group type: EXPERIMENTAL
Intervention: ACURATE neo2 valve implantation
Number of subjects: 250
Study: 37982276

Group type: EXPERIMENTAL
Intervention: sLOX-1 above the median
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein quartile 4 (≥4.0 mg/L)
Number of subjects: 327
Study: 37982381

Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulation with LMWH (13.2%) or DOAC (7.1%) for patients with higher VTE risk
Number of subjects: 1878

Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 1878

Group type: EXPERIMENTAL
Intervention: Prophylaxis duration of up to 7 days
Number of subjects: 1878

Group type: EXPERIMENTAL
Intervention: Single LMWH injection
Number of subjects: 1878

Group type: EXPERIMENTAL
Intervention: Anticoagulation duration based on individual VTE risk
Number of subjects: 1878
Study: 37982388

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 1261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1261
Study: 37982547

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 190
Study: 37982575

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Oral ERα degraders
Number of subjects: 69
Study: 37982583

Group type: EXPERIMENTAL
Intervention: Repeated Measures Model (RMM)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Empirical Cumulative Distribution Function (eCDF)
Number of subjects: 688
Study: 37982585

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg twice a day (BID) with rifampicin 600 mg OD (PK3)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily (OD) with rifampicin 600 mg (PK2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg BID with rifampicin 1200 mg OD (PK4)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir 300/100 mg OD (baseline, PK1)
Number of subjects: 26
Study: 37982593

Group type: EXPERIMENTAL
Intervention: Sip Til Send protocol (liberal hydration with water)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fully fasting (standard fasting)
Number of subjects: 58
Study: 37982763

Group type: EXPERIMENTAL
Intervention: Convergence Insufficiency (CI)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Binocularly Normal Controls (BNC)
Number of subjects: 49
Study: 37982827

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day for 21 days per cycle, administered for two cycles during IMRT) + Cetuximab + Intensity-modulated radiotherapy (IMRT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Palbociclib + Cetuximab + IMRT
Number of subjects: 27
Study: 37982826

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 2061

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2061
Study: 37982865

Group type: EXPERIMENTAL
Intervention: Myocardial injury (acute and chronic)
Number of subjects: 2714

Group type: EXPERIMENTAL
Intervention: NSTEMI Type 1
Number of subjects: 2714

Group type: EXPERIMENTAL
Intervention: ST-elevation MI
Number of subjects: 2714

Group type: EXPERIMENTAL
Intervention: Acute myocardial injury
Number of subjects: 2714

Group type: EXPERIMENTAL
Intervention: Chronic myocardial injury
Number of subjects: 2714

Group type: COMPARATOR
Intervention: Reference group (other reasons for chest pain)
Number of subjects: 2714
Study: 37982892

Group type: EXPERIMENTAL
Intervention: Relaxing music group (RMG)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Turkish classical music group (TCMG)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 75
Study: 37982966

Group type: EXPERIMENTAL
Intervention: Pooled Upadacitinib 15 mg (UPA15)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pooled Upadacitinib 30 mg (UPA30)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Adalimumab 40 mg (ADA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Methotrexate monotherapy (MTX)
Number of subjects: 11
Study: 37982982

Group type: EXPERIMENTAL
Intervention: Educational brochure on deprescribing mailed to patients, clinician notification about brochure mailings, and monthly educational tip sheets for primary care clinicians.
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 3012

Group type: EXPERIMENTAL
Intervention: Educational brochure on deprescribing.
Number of subjects: 3012
Study: 37983082

Group type: COMPARATOR
Intervention: Monotherapy (4PBA, CPX, lumacaftor, cavosonstat, FDL169)
Number of subjects: 4781

Group type: COMPARATOR
Intervention: Dual therapy (lumacaftor-ivacaftor, tezacaftor-ivacaftor)
Number of subjects: 4781

Group type: COMPARATOR
Intervention: Triple therapy (elexacaftor-tezacaftor-ivacaftor/deutivacaftor, VX-659-tezacaftor-ivacaftor/deutivacaftor, VX-440-tezacaftor-ivacaftor, VX-152-tezacaftor-ivacaftor)
Number of subjects: 4781
Study: 37983228

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen and fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo and fentanyl
Number of subjects: 60
Study: 37983375

Group type: EXPERIMENTAL
Intervention: GP-2250 (misetionamide) administered daily for 28 days at doses of 500 mg/kg, 1000 mg/kg, and 250 mg/kg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vehicle (10 ml/kg) administered daily for 28 days
Number of subjects: 300
Study: 37983762

Group type: EXPERIMENTAL
Intervention: Novel transaxillary thyroidectomy procedure
Number of subjects: 116

Group type: COMPARATOR
Intervention: Open thyroidectomy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Gasless transaxillary endoscopic thyroidectomy (GTET)
Number of subjects: 116
Study: 37983769

Group type: EXPERIMENTAL
Intervention: 3-in-1 single capsule with bismuth, metronidazole, and tetracycline
Number of subjects: 2852

Group type: EXPERIMENTAL
Intervention: Quadruple therapy with bismuth
Number of subjects: 2852

Group type: EXPERIMENTAL
Intervention: Concomitant regimen with tinidazole
Number of subjects: 2852

Group type: EXPERIMENTAL
Intervention: Triple therapy with levofloxacin
Number of subjects: 2852

Group type: EXPERIMENTAL
Intervention: 3-in-1 single capsule
Number of subjects: 2852

Group type: EXPERIMENTAL
Intervention: Triple schedules, sequential, or concomitant regimen with metronidazole
Number of subjects: 2852
Study: 37983823

Group type: EXPERIMENTAL
Intervention: Carotid FTc combined with perioperative fluid therapy (8 ml/kg of balanced crystalloids)
Number of subjects: 177

Group type: COMPARATOR
Intervention: No perioperative fluid therapy
Number of subjects: 177
Study: 37983985

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention on food hygiene practices
Number of subjects: 2705

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2705
Study: 37984383

Group type: EXPERIMENTAL
Intervention: Vosoritide (30·0 μg/kg for infants aged 0-23 months; 15·0 μg/kg for children aged 24-59 months)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vosoritide
Number of subjects: 75
Study: 37984453

Group type: EXPERIMENTAL
Intervention: RPT193 (oral CCR4 antagonist), once-daily treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 37984741

Group type: COMPARATOR
Intervention: 100 g prune/d
Number of subjects: 183

Group type: COMPARATOR
Intervention: 50 g prune/d
Number of subjects: 183
Study: 37984941

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CCTA)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Baseline characteristics
Number of subjects: 2000
Study: 37984940

Group type: EXPERIMENTAL
Intervention: Angiotensin II as a second-line vasopressor infusion during liver transplantation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo as the second-line vasopressor infusion during liver transplantation.
Number of subjects: 0
Study: 37984956

Group type: EXPERIMENTAL
Intervention: Prostate-specific membrane antigen (PSMA) combined model
Number of subjects: 0
Study: 37984961

Group type: EXPERIMENTAL
Intervention: Breast Cancer Risk Assessment Tool (BCRAT) scores presented during counselling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Video-recorded consultations and semi-structured interviews
Number of subjects: 30
Study: 37985341

Group type: EXPERIMENTAL
Intervention: Vitamin C, thiamine, and hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37985359

Group type: EXPERIMENTAL
Intervention: Ibrutinib (oral Bruton tyrosine kinase inhibitor), lenalidomide (15 mg days 1-21 cycle 1; 20 mg cycles 2-12), and rituximab (375 mg/m2) for 12 cycles of 28 days each.
Number of subjects: 48
Study: 37985382

Group type: EXPERIMENTAL
Intervention: Shared decision making program for fertility preservation (FP)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1100
Study: 37985386

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with immunotherapy (NACI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 99
Study: 37985501

Group type: EXPERIMENTAL
Intervention: TL (docetaxel + lobaplatin)
Number of subjects: 128

Group type: COMPARATOR
Intervention: TPF (docetaxel + cisplatin + 5-fluorouracil)
Number of subjects: 128
Study: 37985592

Group type: EXPERIMENTAL
Intervention: Social media recruitment through a Facebook page emphasizing community engagement
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Messages describing community involvement
Number of subjects: 429
Study: 37985697

Group type: EXPERIMENTAL
Intervention: 2-mg CPC buccal tablet
Number of subjects: 10
Study: 37985817

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune-checkpoint blockade
Number of subjects: 0
Study: 37985872

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham mindfulness-meditation
Number of subjects: 59
Study: 37985968

Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg (continuation from placebo)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg (continuation from placebo)
Number of subjects: 865

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 865
Study: 37985994

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence in MASLD(+) patients
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence in MASLD(-) patients
Number of subjects: 2000
Study: 37986021

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise program (60-80% of maximum heart rate), including two supervised sessions of 60 min per week and one home training session per week.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Online video lesson on lifestyle guidance offered to the intervention group.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 150
Study: 37986090

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (1 MHz, 1.5W/cm2, 10 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short wave diathermy (27.12 MHz, wavelength 11.06 m, induction technique, 20 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (hotpack, TENS and therapeutic exercises alone)
Number of subjects: 0
Study: 37986100

Group type: EXPERIMENTAL
Intervention: Mobilisation duration ≥ 40 min
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Mobilisation duration > 40 min
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Mobilisation parameters including level of mobilisation
Number of subjects: 684
Study: 37986149

Group type: EXPERIMENTAL
Intervention: Home-based self-management program (6 sessions over 11 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Education about stroke and usual care (1 session)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Home-based self-management program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Education about stroke and usual care
Number of subjects: 24
Study: 37986155

Group type: COMPARATOR
Intervention: ECOHIS (Early Childhood Oral Health Impact Scale)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Child-OIDP (Child Oral Impact on Daily Performance)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Orofacial pain
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Impaired physical health
Number of subjects: 314
Study: 37986157

Group type: EXPERIMENTAL
Intervention: Cardiac injury during ICU stay
Number of subjects: 198

Group type: COMPARATOR
Intervention: Men
Number of subjects: 198

Group type: COMPARATOR
Intervention: Women
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Patients with cardiac injury
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Lymphopenia on ICU admission
Number of subjects: 198
Study: 37986188

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instruction to Increase Water Consumption
Number of subjects: 0
Study: 37986191

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome data collection tool
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Standardized side effect counseling
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2000
Study: 37986460

Group type: EXPERIMENTAL
Intervention: DHS/GC × GC-O-MS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salt addition during extraction
Number of subjects: 0
Study: 37986556

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg i.v. bi-weekly for up to 12 months (Part 1)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Sequential addition of ipilimumab 1 mg/kg three-weekly for four doses to nivolumab (Part 2)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 83
Study: 37986836

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Chemotherapy and Endocrine therapy
Number of subjects: 256
Study: 37986887

Group type: EXPERIMENTAL
Intervention: Novel 4-month treatment regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 37986904

Group type: EXPERIMENTAL
Intervention: LC→LF diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: LF→LC diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MPF→UPF diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: UPF→MPF diet
Number of subjects: 20
Study: 37986911

Group type: EXPERIMENTAL
Intervention: GD2BATs (anti-CD3 x anti-GD2 bispecific antibody armed T cells)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GD2BATs
Number of subjects: 9
Study: 37986940

Group type: EXPERIMENTAL
Intervention: Whole food, plant-based diet (WFPB)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 37987108

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after three months of dual antiplatelet therapy (DAPT)
Number of subjects: 2993

Group type: COMPARATOR
Intervention: DAPT for the entire 12 months
Number of subjects: 2993
Study: 37987186

Group type: EXPERIMENTAL
Intervention: T2D patients
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Premenopausal women with T2D
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with T2D
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Men with T2D ≥50 years
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Men with T2D <50 years
Number of subjects: 1446
Study: 37987359

Group type: EXPERIMENTAL
Intervention: Heparinase I treatment
Number of subjects: 0
Study: 37987871

Group type: EXPERIMENTAL
Intervention: High-normal MAP
Number of subjects: 227

Group type: COMPARATOR
Intervention: Low-normal MAP
Number of subjects: 227
Study: 37987893

Group type: EXPERIMENTAL
Intervention: QL1207
Number of subjects: 366

Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 366
Study: 37988150

Group type: EXPERIMENTAL
Intervention: Well Feet mHealth app intervention for 1 month
Number of subjects: 40
Study: 37988255

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Abrocitinib (both doses)
Number of subjects: 942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942